Simple squamous epithelium

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

Retrieved on: 
Monday, April 1, 2024
HER2, IHC, CNTN4, Mutation, Genome, NSCLC, Immunotherapy, Breast, Patient, Neoplasm, ERBB2, Biomarker, Cancer, AI, Pembrolizumab, Medicine, AACR, Simple squamous epithelium, Therapy, Stomach, PD-L1, Annual general meeting

SEOUL, South Korea, April 1, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, California, from April 5 to 10.

Key Points: 
  • In a poster presentation, Lunit's AI-powered HER2 analyzer, Lunit SCOPE HER2's precision shines through its analysis of 194,259 pan-cancer samples, correlating different ERBB2 mutations with changes in HER2 protein expression.
  • Through detailed HER2 intensity examination, the AI analysis highlighted that, among ERBB2-mutated cases with HER2 IHC images, a higher proportion of HER2 3+ tumor cells was observed in S310x and ex20ins cases compared to others.
  • Similarly, high HER2 expression was observed in both S301x and ex20ins cases compared to other mutation cases.
  • Visit Lunit at booth 808 to explore how the Lunit SCOPE suite is revolutionizing oncology research and clinical practice.

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Retrieved on: 
Sunday, October 15, 2023
Congress, Partnership, Senior, Cancer, Zolbetuximab, Astellas Pharma, Abstract, Brentuximab vedotin, Leuprorelin, GEJ, TSE, BCR, Patient, Oncology, ESMO, Quality of life (healthcare), Merck, Seagen, GLOW, Adenocarcinoma, European Society for Medical Oncology, Neoplasm, Prostate, HER2, Simple squamous epithelium, Research, Pharmaceutical industry

TOKYO, Oct. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research results during the European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, showcasing the company's focus on making a meaningful difference for people living with hard-to-treat cancers. A total of 13 abstracts will be presented, highlighting data from two established medicines and one investigational therapy, across prostate, urothelial, and gastric/gastroesophageal junction (GEJ) cancers.

Key Points: 
  • Data include three late-breaking abstracts, underscoring Astellas' efforts to potentially redefine expectations for patients across its oncology portfolio
    TOKYO, Oct. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research results during the European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, showcasing the company's focus on making a meaningful difference for people living with hard-to-treat cancers.
  • A total of 13 abstracts will be presented, highlighting data from two established medicines and one investigational therapy, across prostate, urothelial, and gastric/gastroesophageal junction (GEJ) cancers.
  • "At Astellas, we're working to change the course of cancer care, including through scientific advancements to address pressing unmet needs.
  • During ESMO, we will share updated data from two Phase 3 clinical studies, highlighting important clinical data of zolbetuximab in gastric and GEJ cancer patients whose tumors are CLDN18.2-positive."

Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Retrieved on: 
Monday, March 6, 2023
Ovarian cancer, CD70, Mesothelin, MPM, ADAP, TCR, Specialization, IND, Webcast, Engineering, Platinum, Ovary, Neoplasm, Growth, Mesothelioma, Synovial sarcoma, TNBC, Therapy, Nivolumab, JAMA Otolaryngology–Head & Neck Surgery, PRAME, Patient, TD, Truc, Simple squamous epithelium, Carcinoma, Survival, Cancer, EST, SPEAR, BLA, Otorhinolaryngology, Overalls, PDUFA, Bank, Holding company, Pharmaceutical industry, Vaccine, Fine chemical, Birth control, Cryptocurrency, EU

Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: “This strategic combination takes two technologically and culturally aligned companies at the forefront of their fields and combines them to create a preeminent cell therapy company for solid tumors.

Key Points: 
  • Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: “This strategic combination takes two technologically and culturally aligned companies at the forefront of their fields and combines them to create a preeminent cell therapy company for solid tumors.
  • The combined company will drive forward its pipeline of cell therapies aimed at treating multiple cancers with high unmet medical needs.
  • Focus and specialization are critical in the cell therapy space and we believe the combined company has the technologies necessary to succeed.
  • The combined company has a team of leading cell therapy experts led by Adrian Rawcliffe, the CEO of Adaptimmune.

Caris Life Sciences to Showcase Research with Leading Cancer Centers at ASCO Genitourinary Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for Patients

Retrieved on: 
Monday, February 13, 2023
MBA, Carcinoma, Prostate, Renal cell carcinoma, Physician, Abstract, Simple squamous epithelium, POA, Metastasis, Tumor microenvironment, Patient, Database, Impact, Research, Intelligence, ATM, FACP, Neoplasm, Society, Tabletop, Cancer, American Society of Clinical Oncology, RCC, ASCO, Pharmaceutical industry, Medical imaging

IRVING, Texas, Feb. 13, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced that the company and partners within the Caris Precision Oncology Alliance™ (POA) will collectively present five studies across three tumor types at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, February 16-18, 2023 in San Francisco (Tabletop #50).

Key Points: 
  • "The findings represent important observations in prostate, urothelial, and renal cancers, which could lead to novel treatment strategies and knowledge that improve patient outcomes."
  • These foundational discoveries provide key insights into advanced cancer and support the development of precision oncology approaches in advanced genitourinary tumors to better serve cancer patients."
  • (Poster Number: K8)
    Poster and abstract summaries highlighting this research will be available onsite at Caris' Tabletop #50.
  • The Caris Precision Oncology Alliance includes 77 cancer centers and academic institutions in the United States and beyond.